KA/EN
Register
Medicines reference
Search
Search
Product

Gefriderm

Favourites

Marbofloxacin + Ketoconazole + Prednisolone · ALPHAVET Zrt.

1 form: aerosol / spray. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Aerosol / spray · Dog Dog 2 sprays
One spray is approximately 0.1 ml. Clean first; hold 10 cm away. Divide larger lesions into 25 cm² zones, maximum four zones simultaneously. Focal proved mixed infection only; reassess at day 7 and change treatment if signs remain after day 14.
 · two sprays per 25 cm² twice daily for 7 days; continue only to maximum 14 days if unresolved		 two sprays per 25 cm² twice daily for 7 days; continue only to maximum 14 days if unresolved Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Gefriderm, Aerosol / spray

cutaneous spray solution, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.3/10
Good
vetman assessment

Gefriderm

cutaneous spray solution, for dogs
Assessed clinical scopeDog · Label-concordant treatment of a proved focal acute superficial mixed infection in dogs: marbofloxacin-susceptible Pseudomonas aeruginosa or Staphylococcus pseudintermedius plus ketoconazole-susceptible Malassezia pachydermatis · On the skin
Care settingVeterinarian-directed clinic/home treatment after cytology, organism identification and susceptibility testing, with lesion preparation, exposure control and day-7/day-14 reassessment.
vetman score 7.3/10 Good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A well-documented licensed option for a narrow, proved focal mixed bacterial-and-Malassezia dermatitis. Its value disappears when used empirically, on diffuse/deep disease, or where an antiseptic or narrower agent is suitable.

Regulatory and scientific credibility8.0/10

Current exact UK and EU regulator records provide full composition, authorisation, dose, target-animal PK and safety, while the exact EU public assessment report exposes the pivotal efficacy review; national EU authorisations are traceable, but Georgia and the US have no exact authorisation and no independent published exact-product trial was located.

Clinical efficacy7.5/10

The regulator-reviewed exact-product GCP field trial included 56 eligible dogs, confirmed mixed infections, an active comparator and demonstrated non-inferiority with clinical cure by day 14. This supports efficacy within the narrow proved mixed-infection scope, while antiseptic-first guidance, category-B fluoroquinolone stewardship and the absence of an independent published trial limit broader value.

Safety and tolerability6.5/10

Very rare mild erythema, very low one-zone plasma exposure and a five-times one-zone tolerance study are reassuring, but multi-zone overdose was not studied and steroid-related delayed healing, epidermal thinning/adrenal suppression, reproductive risk, licking and handler inhalation/contact risks remain material.

Clinical practicality7.0/10

A metered spray is practical for focal painful or folded skin and the twice-daily 7-day plan is clear, but clipping/cleaning, 25 cm² measurement, four-zone ceiling, gloves, ventilation, lick prevention, no bathing and 20-minute child/contact restriction add substantial workflow.

Full-course cost-effectiveness-

No verified current Georgian patient-adjusted full-course price is available, so cost is excluded.

Important safety and use flags

  • Veterinary prescription medicine authorised for dogs in GB and EU national markets. Exact-product registers dated 2026-10-15 record it as not authorised in Georgia and the US; this does not negate the GB/EU dossier.
  • Use only when cytology and organism identification show a focal mixed infection: susceptible Pseudomonas or Staphylococcus plus susceptible Malassezia. Do not use for empiric, bacterial-only, yeast-only, diffuse, deep, sterile or noninfectious disease.
  • Marbofloxacin is an EMA category B Restrict fluoroquinolone. Prefer a suitable antiseptic or narrower option; use culture/susceptibility, avoid quinolone-resistant isolates and stop unnecessary components as soon as the mixed indication no longer exists.
  • Clean, clip and remove exudate/debris before dosing. Treat two sprays per 25 cm² twice daily; split larger lesions into measured zones and never exceed four zones simultaneously.
  • Treat seven days and reassess. Continue only if still indicated, never beyond 14 days; persistent infection after day 14 requires diagnosis and a different appropriate product, not automatic extension.
  • Avoid eyes, mucosa, open lesions and wounds. Prevent self- and cross-licking, separate treated dogs when needed, keep hair short and do not bathe or shampoo during administration.
  • Not recommended in pregnancy or lactation; safety is unestablished and ketoconazole was teratogenic/embryotoxic in laboratory animals. Avoid known hypersensitivity to any active or excipient.
  • Prolonged or intensive topical prednisolone can thin epidermis, delay healing and suppress adrenal function. Monitor erythema, irritation, delayed repair and systemic glucocorticoid signs, especially with multiple zones or comorbidity.
  • Avoid concurrent low-pH products because they may inhibit marbofloxacin. No interaction studies establish combined-product safety or efficacy; review every topical/systemic antimicrobial, antifungal and corticosteroid.
  • Handler safety: wear single-use impermeable gloves, spray outdoors or with good ventilation, avoid inhalation/skin/eye contact and flames, and do not let children touch the dog until dry for at least 20 minutes. Pregnant people or those trying to conceive must not administer it.
Assessment sources
  1. Gefriderm UK SPC2026
  2. Gefriderm VMD record2026
  3. Gefriderm EU record2026
  4. Gefriderm EU PuAR2020
  5. ISCAID canine pyoderma 20252025
  6. MSD pyoderma2025
  7. EMA AMEG category B2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin1.025 mg/ml Ketoconazole2.041 mg/ml Prednisolone0.926 mg/ml
Formulation Type
Aerosol / spray
Administration route
On the skin
Manufacturer
ALPHAVET Zrt. · Hungary
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 51645/4000
Verified on: 22 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Clean/clip and remove exudate/debris; shake and hold 10 cm away. Apply two sprays per 25 cm² twice daily for seven days. If unresolved at day 7, continue only to day 14. Divide larger lesions into 25 cm² zones; maximum four zones simultaneously. Re-evaluate and change treatment if infection persists after 14 days.
DoseSpeciesWeightRouteFrequencySource
2 sprays
One spray is approximately 0.1 ml. Clean first; hold 10 cm away. Divide larger lesions into 25 cm² zones, maximum four zones simultaneously. Focal proved mixed infection only; reassess at day 7 and change treatment if signs remain after day 14.
 Dog Any weight On the skin two sprays per 25 cm² twice daily for 7 days; continue only to maximum 14 days if unresolved
Gefriderm UK SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Gefriderm cutaneous spray solution for dogs - current UK summary of product characteristics
Veterinary Medicines Directorate, 2026
Active substance doses, with sources
Active substance Marbofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2 mg/kg Dog, Cat Bacterial Infection; Skin and Soft Tissue Infection By mouth / Subcutaneous once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl P 5 mg Tablet for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
2.75–5.5 mg/kg Dog, Cat Bacterial Infection By mouth once daily
FDA 2019
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Zeniquin (marbofloxacin) Tablets - FDA-approved animal drug label, NADA 141-151
US Food and Drug Administration, via DailyMed, 2019
5.5 mg/kg Dog Skin and Soft Tissue Infection By mouth once daily
ISCAID 2025
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)
Veterinary Dermatology, 2025
2 mg/kg Dog Skin and Soft Tissue Infection Subcutaneous Single dose
VMD Marbocyl SA SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Marbocyl SA 200 mg powder and solvent for solution for injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
Active substance Prednisolone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.1–2 mg/kg Dog, Cat Inflammation By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Prednicare 5 mg Tablets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2026
0.5–4 mg/kg Dog, Cat Immune-Mediated Disease By mouth once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Prednicortone 5 mg Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
0.5–1 mg/kg Dog, Cat Inflammation Intramuscular Single dose
VMD SPC 2023
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Cortico Veyxin 10 mg/ml Suspension for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2023

Ketoconazole: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical Marbofloxacin
    Do not use in animals hypersensitive to fluoroquinolones or any product component. Do not use where quinolone resistance is confirmed; cross-resistance among fluoroquinolones is almost complete.
    Sources: VMD SPC · VMD · FDA
  • Critical Marbofloxacin (Dog)
    Age limits differ by product: one label prohibits use in dogs younger than 12 months and in slow-growing large breeds younger than 18 months; another uses 8 months for small/medium breeds, 12 months for large breeds, and 18 months for giant breeds. Fluoroquinolones can erode articular cartilage in growing dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning Marbofloxacin
    Use with caution in dogs or cats with epilepsy because fluoroquinolones can cause neurological adverse effects. Overdose may cause acute neurological disturbances requiring symptomatic management.
    Sources: VMD SPC · VMD
  • Warning Marbofloxacin
    Safety in pregnant dogs and cats has not been established. Use only after a benefit-risk assessment. Studies in pregnant rats and rabbits found no adverse effects, but target-species studies are lacking; this means unassessed, not proven safe.
    Sources: VMD SPC · VMD
  • Warning Marbofloxacin
    Safety during lactation in dogs and cats has not been established. Use only after a benefit-risk assessment; the reviewed labels provide pregnancy data but no separate lactation statement.
    Sources: FDA
  • Critical Prednisolone
    An uncontrolled viral, fungal, or parasitic infection is an absolute contraindication. The parasitic-infection restriction is specified on the Prednicare label.
  • Critical Prednisolone
    Diabetes mellitus is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Hyperadrenocorticism is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Osteoporosis is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Corneal ulceration is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Glaucoma is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Hypersensitivity to prednisolone or any excipient is an absolute contraindication on the Prednicare and Prednicortone labels.
    Sources: Product label
  • Critical Prednisolone
    Burn injury is listed as a contraindication on the Prednicortone label but not on the other two reviewed labels.
    Sources: Product label
  • Critical Prednisolone
    Cataract is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Hypocalcaemia is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Hypertension is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Pancreatitis is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    A poorly healing wound or fracture is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    General immunodeficiency is listed as a contraindication on the Cortico Veyxin label.
    Sources: Product label
  • Critical Prednisolone
    Gastrointestinal ulceration is an absolute contraindication on all three reviewed labels. Concomitant corticosteroid and NSAID treatment further increases the risk of ulceration; see the interaction warnings.
    Sources: Product label
  • Critical Prednisolone
    cardiac or renal dysfunction
    Sources: Product label
  • Critical Prednisolone
    Severe renal impairment is an absolute contraindication on the Prednicare label.
    Sources: Product label
  • Critical Prednisolone
    Do not use during pregnancy. Some corticosteroid products specify this restriction for the final third of gestation.
  • Warning Prednisolone
    Use in growing animals carries a risk of growth retardation, suppression of bone growth, and damage to the bone matrix.
  • Warning Prednisolone
    Do not use with a live attenuated vaccine because corticosteroids suppress the immune response to vaccination. The Prednicortone label also prohibits use within 2 weeks after vaccination.
  • Warning Prednisolone
    very rare

Known Drug Interactions

  • Contraindicated Meloxicam + Prednisolone
    Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.
    Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.
    Sources: Product label
  • Contraindicated Robenacoxib + Prednisolone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Marbofloxacin + Aminophylline
    Theophylline metabolism is inhibited by... enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Prednisolone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Prednisolone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Furosemide + Prednisolone
    Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.
    Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Prednisolone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Marbofloxacin + Theophylline
    Fluoroquinolones can increase serum theophylline concentrations. When marbofloxacin and theophylline are used together, monitor theophylline closely because its therapeutic range is narrow and toxicity may occur.
    Recommendation: If concomitant use is necessary, monitor serum theophylline and be prepared to reduce its dose. Alternatively, choose another antibiotic.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (91 more) Hide additional products

Same therapeutic group 91

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗